pmcc logo smlHere are the staff publications for October 2017, compiled 6th November 2017.



Here are the staff publications for October 2017.

Compiled by the Health Sciences Library (RMH, RWH, PMCC and Victorian Mental Health) 6th November 2017.

  1. Adler NR, Wolfe R, Kelly JW, Haydon A, McArthur GA, McLean CA, Mar VJ. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. British Journal of Cancer 2017;117:1026-35.
  2. Ahmed MU, Maurya AK, Cheng L, Jorge EC, Schubert FR, Maire P, Basson MA, Ingham PW, Dietrich S. Engrailed controls epaxial-hypaxial muscle innervation and the establishment of vertebrate three-dimensional mobility. Developmental Biology 2017;430:90-104.
  3. Beavis PA, Sek K, Darcy PK. A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells. Molecular Therapy 2017;25:1997-8.
  4. Behrenbruch C, Hollande F, Thomson B, Michael M, Warrier SK, Lynch C, Heriot A. Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer. ANZ Journal of Surgery 2017;87:665-70.
  5. Bjornmalm M, Thurecht KJ, Michael M, Scott AM, Caruso F. Bridging Bio-Nano Science and Cancer Nanomedicine. ACS Nano 2017;11:9594-613.
  6. Blaschke S, O'Callaghan CC, Schofield P. Nature-based care opportunities and barriers in oncology contexts: a modified international e-Delphi survey. BMJ Open 2017;7:e017456.
  7. Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. Cancer Immunology Research 2017;5:871-84.
  8. Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017;549:101-5.
  9. Butler LA, Tam CS, Seymour JF. Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. Blood Reviews 2017;31:318-27.
  10. Cheah CY, Joske D, Cull G, Gilbertson M, Opat SS, Tam CS, Wirth A, Seymour JF. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. British Journal of Haematology 2017;178:991-4.
  11. Chueh AC, Tse JWT, Dickinson M, Ioannidis P, Jenkins L, Togel L, Tan B, Luk I, Davalos-Salas M, Nightingale R, Thompson MR, Williams BRG, Lessene G, Lee EF, Fairlie WD, Dhillon AS, Mariadason JM. ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types. Clinical Cancer Research 2017;23:5573-84.
  12. Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research 2017;23:5339-48.
  13. Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS. Ibrutinib may impair serological responses to influenza vaccination. Haematologica 2017;102:e397-e9.
  14. Edbrooke L, Aranda S, Granger CL, McDonald CF, Krishnasamy M, Mileshkin L, Irving L, Braat S, Clark RA, Gordon I, Denehy L. Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer - protocol for a phase II randomised controlled trial. BMC Cancer 2017;17:663.
  15. Everitt S, Ball D, Hicks RJ, Callahan J, Plumridge N, Trinh J, Herschtal A, Kron T, Mac Manus M. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival. International Journal of Radiation Oncology Biology Physics 2017;99:947-55.
  16. Everitt S, Callahan J, Obeid E, Hicks RJ, Mac Manus M, Ball D. Acute radiation oesophagitis associated with 2-deoxy-2-[18F]fluoro-d-glucose uptake on positron emission tomography/CT during chemo-radiation therapy in patients with non-small-cell lung cancer. Journal of Medical Imaging and Radiation Oncology 2017;61:682-8.
  17. Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS, investigators T-A. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery 2017;7:1006-17.
  18. Habash M, Bohorquez LC, Kyriakou E, Kron T, Martin OA, Blyth BJ. Clinical and Functional Assays of Radiosensitivity and Radiation-Induced Second Cancer. Cancers (Basel) 2017;9.
  19. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden G, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, Andre F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology 2017;24:311-35.
  20. Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Horsch D, Tiensuu Janson E, Ramage J, Antibes Consensus Conference p. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017;105:295-309.
  21. Hofman MS. Accuracy in the Eye of the Beholder: Can We Improve Agreement in Prostate Cancer Diagnostics with PSMA PET/CT? Journal of Nuclear Medicine 2017;58:1615-6.
  22. House IG, House CM, Brennan AJ, Gilan O, Dawson MA, Whisstock JC, Law RH, Trapani JA, Voskoboinik I. Regulation of perforin activation and pre-synaptic toxicity through C-terminal glycosylation. EMBO Reports 2017;18:1775-85.
  23. Huang S, Theophilus M, Cui J, Bell SW, Wale R, Chin M, Farmer C, Warrier SK. Colonic transit: what is the impact of a diverting loop ileostomy? ANZ Journal of Surgery 2017;87:795-9.
  24. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. British Journal of Haematology 2017;178:286-91.
  25. Kearney CJ, Lalaoui N, Freeman AJ, Ramsbottom KM, Silke J, Oliaro J. PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. Cell Death and Differentiation 2017;24:1705-16.
  26. Kiss N. Nutrition support and dietary interventions for patients with lung cancer: current insights. Lung Cancer (Auckl) 2016;7:1-9.
  27. Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, Maimon O, Pattison DA, Gross DJ, Hicks RJ. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 2017;102:3278-87.
  28. Kumarasinghe MP, Morey A, Bilous M, Farshid G, Francis G, Lampe G, McCue G, Von Neumann-Cosel V, Fox SB. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. Pathology 2017;49:575-81.
  29. Lawrentschuk N. Urological outcomes in Australia and New Zealand: who's watching? BJU International 2017;120 Suppl 3:5.
  30. Lawrentschuk N. Editorial Comment. Journal of Urology 2017;198:1075-6.
  31. Le Roux PY, Siva S, Callahan J, Claudic Y, Bourhis D, Steinfort DP, Hicks RJ, Hofman MS. Automatic delineation of functional lung volumes with 68Ga-ventilation/perfusion PET/CT. EJNMMI Res 2017;7:82.
  32. Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M, Embrace, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S, Collaborators GS, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomaki K, Khan S, Nevanlinna H, van Asperen CJ, Hebon, Vaszko T, Kasler M, Olah E, Balmana J, Gutierrez-Enriquez S, Diez O, Teule A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H, Investigators KC, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology 2017;35:2240-50.
  33. Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal 2017;47:938-51.
  34. Lee YC, Kroon R, Koczwara B, Haines I, Francis K, Millward M, Kefford R, Olver I, Mileshkin L. Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia. Internal Medicine Journal 2017;47:888-93.
  35. Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast C. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers. European Journal of Cancer 2017;84:114-20.
  36. Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Clinical Cancer Research 2017;23:4086-94.
  37. Lim K, van Dyk S, Khaw P, Veera J, Mileshkin L, Ohanessian L, Harrison M, Vinod SK. Patterns of practice survey for brachytherapy for cervix cancer in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology 2017;61:674-81.
  38. Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kummel S, Steger G, Gombos A, Lux M, Piccart MJ, Von Minckwitz G, Baselga J, Loi S. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). European Journal of Cancer 2017;85:133-45.
  39. Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, Andre F, Harbeck N, Verma S, Folkerd E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH, Dowsett M. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist 2017;22:1028-38.
  40. Macesic N, Morrissey CO, Liew D, Bohensky MA, Chen SC, Gilroy NM, Milliken ST, Szer J, Slavin MA. Is a biomarker-based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients? Medical Mycology 2017;55:705-12.
  41. Manent J, Banerjee S, de Matos Simoes R, Zoranovic T, Mitsiades C, Penninger JM, Simpson KJ, Humbert PO, Richardson HE. Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species. Oncogene 2017;36:5658-60.
  42. Manning TG, Cheung E, Perera M, Christidis D, O'Brien JS, Mitchell C, Bolton DM, Lawrentschuk N. Atypical Small Acinar Proliferation and High-grade Prostatic Intraepithelial Neoplasia in the Era of Multiparametric Magnetic Resonance Imaging: A Contemporary Review. Urology 2017;107:5-10.
  43. Mar VJ, Chamberlain AJ, Kelly JW, Murray WK, Thompson JF. Clinical practice guidelines for the diagnosis and management of melanoma: melanomas that lack classical clinical features. Medical Journal of Australia 2017;207:348-50.
  44. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trneny M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England Journal of Medicine 2017;377:1331-44.
  45. Marx W, Kiss N, McKavanagh D, Isenring E. Attitudes, beliefs and behaviours of Australia dietitians regarding dietary supplements: A cross-sectional survey. Complement Ther Clin Pract 2016;25:87-91.
  46. McArthur GA, Mohr P, Ascierto PA, Arance A, Banos Hernaez A, Kaskel P, Weichenthal M, Shinde R, Stevinson K. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). Oncologist 2017;22:951-62.
  47. McQuerry JA, Chang JT, Bowtell DDL, Cohen A, Bild AH. Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. Journal of Molecular Medicine (Berl) 2017;95:1167-78.
  48. Oberoi DV, White VM, Seymour JF, Prince HM, Harrison S, Jefford M, Winship I, Hill DJ, Bolton D, Millar J, Wong Doo N, Kay A, Giles G. Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients. European Journal of Haematology 2017;99:423-30.
  49. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncology 2017;18:1182-91.
  50. Paquet-Fifield S, Roufail S, Zhang YF, Sofian T, Byrne DJ, Coughlin PB, Fox SB, Stacker SA, Achen MG. The fibrinolysis inhibitor alpha2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. Growth Factors 2017;35:61-75.
  51. Pascoe MC, Thompson DR, Jenkins ZM, Ski CF. Mindfulness mediates the physiological markers of stress: Systematic review and meta-analysis. Journal of Psychiatric Research 2017;95:156-78.
  52. Pascoe MC, Thompson DR, Ski CF. Yoga, mindfulness-based stress reduction and stress-related physiological measures: A meta-analysis. Psychoneuroendocrinology 2017;86:152-68.
  53. Paterson R, Phillips KA. Genetic testing in women with breast cancer: implications for treatment. Expert Reviews in Anticancer Therapy 2017;17:991-1002.
  54. Pepin G, Nejad C, Ferrand J, Thomas BJ, Stunden HJ, Sanij E, Foo CH, Stewart CR, Cain JE, Bardin PG, Williams BRG, Gantier MP. Topoisomerase 1 Inhibition Promotes Cyclic GMP-AMP Synthase-Dependent Antiviral Responses. MBio 2017;8.
  55. Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. European Urology 2017;72:492-5.
  56. Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology 2017;28:2517-25.
  57. Russell PA, Rogers TM, Solomon B, Alam N, Barnett SA, Rathi V, Williams RA, Wright GM, Conron M. Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients. Pathology 2017;49:604-10.
  58. Sampurno F, Earnest A, Millar J, Frydenberg M, Murphy D, Delprado W, Evans S. Population-based study of grade progression in patients who harboured Gleason 3 + 3. World Journal of Urology 2017;35:1689-99.
  59. Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnayan A, de Bono JS. Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clinical Cancer Research 2017;23:6070-7.
  60. Siva S. The Prickly Predicament of Pursuing Pulmonary Polymetastases. International Journal of Radiation Oncology Biology Physics 2017;99:764-5.
  61. Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH, Chesson B, Shaw M, Chander S, Gill S, Brook NR, Lawrentschuk N, Murphy DG, Foroudi F. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU International 2017;120:623-30.
  62. Stokes CM, Elsewaisy O, Pang G, Slavin JL, Schlicht SM, Choong PFM. Diagnostic accuracy of computed tomography-guided biopsy in pathological fractures. ANZ Journal of Surgery 2017;87:600-4.
  63. Teh BW, Harrison SJ, Allison CC, Slavin MA, Spelman T, Worth LJ, Thursky KA, Ritchie D, Pellegrini M. Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. Frontiers in Immunology 2017;8:1247.
  64. Trubiano JA, Thursky KA, Stewardson AJ, Urbancic K, Worth LJ, Jackson C, Stevenson W, Sutherland M, Slavin MA, Grayson ML, Phillips EJ. Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. Clinical Infectious Diseases 2017;65:166-74.
  65. Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, Chambers T, Salgado R, Savas P, Loi S, Birkbak NJ, Sansregret L, Gore M, Larkin J, Quezada SA, Swanton C. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncology 2017;18:1009-21.
  66. Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, Jose V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research 2017;77:5652-63.
  67. Villemagne Sanchez LA, O'Callaghan C, Gough K, Hall K, Kashima Y, Seymour JF, Schofield P, Ross DM. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leukemia & Lymphoma 2018;59:406-15.
  68. Violet JA, Hofman MS. Prostate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer. BJU International 2017;120:310-2.
  69. Wein L, Savas P, Van Geelen C, Caramia F, Moodie K, Joshi S, Loi S. FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor. Annals of Oncology 2017;28:2025-7.
  70. White V, Marco DJT, Bolton D, Davis ID, Jefford M, Hill D, Prince HM, Millar JL, Winship IM, Coory M, Giles GG. Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study. BJU International 2017;120 Suppl 3:6-14.
  71. Wiede F, Dudakov JA, Lu KH, Dodd GT, Butt T, Godfrey DI, Strasser A, Boyd RL, Tiganis T. PTPN2 regulates T cell lineage commitment and alphabeta versus gammadelta specification. Journal of Experimental Medicine 2017;214:2733-58.
  72. Williams SP, Odell AF, Karnezis T, Farnsworth RH, Gould CM, Li J, Paquet-Fifield S, Harris NC, Walter A, Gregory JL, Lamont SF, Liu R, Takano EA, Nowell CJ, Bower NI, Resnick D, Smyth GK, Coultas L, Hogan BM, Fox SB, Mueller SN, Simpson KJ, Achen MG, Stacker SA. Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. Science Signaling 2017;10.
  73. Willoughby LF, Manent J, Allan K, Lee H, Portela M, Wiede F, Warr C, Meng TC, Tiganis T, Richardson HE. Differential regulation of protein tyrosine kinase signalling by Dock and the PTP61F variants. FEBS Journal 2017;284:2231-50.
  74. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine 2017;377:1345-56.
  75. Wong ANM, McArthur GA, Hofman MS, Hicks RJ. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging 2017;44:67-77.
  76. Wongchenko MJ, McArthur GA, Dreno B, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler L, Yan Y, Ribas A. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res 2017;23:5238-45.
  77. Wootten AC, Meyer D, Abbott JM, Chisholm K, Austin DW, Klein B, McCabe M, Murphy DG, Costello AJ. An online psychological intervention can improve the sexual satisfaction of men following treatment for localized prostate cancer: outcomes of a Randomised Controlled Trial evaluating My Road Ahead. Psychooncology 2017;26:975-81.
  78. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ, Group ICW. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clin Oncology 2017;35:3097-104.
  79. Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC, Jr., Group AS. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research 2017;23:5912-22.
  80. Yong CS, Abba Moussa D, Cretenet G, Kinet S, Dardalhon V, Taylor N. Metabolic orchestration of T lineage differentiation and function. FEBS Letters 2017;591:3104-18.
  81. Yong MK, Cameron PU, Slavin M, Morrissey CO, Bergin K, Spencer A, Ritchie D, Cheng AC, Samri A, Carcelain G, Autran B, Lewin SR. Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases 2017;215:1684-94.
  82. Zibaei K, Russell SM. In vitro tracking and intracellular protein distribution in immunology. Immunology & Cell Biology 2017;95:501-5.